Alnylam's Phase 2 KARDIA-2 study shows zilebesiran, added to standard antihypertensives, significantly reduced systolic blood pressure in inadequately controlled hypertension patients.

Alnylam presents positive results from the KARDIA-2 Phase 2 study of zilebesiran, added to standard of care antihypertensives in patients with inadequately controlled hypertension. The study met its primary endpoint, demonstrating clinically significant additive reductions in ambulatory systolic blood pressure of up to 12.1 mmHg at month 3. Zilebesiran also showed an encouraging safety and tolerability profile when added to standard of care antihypertensives.